Cardinal Health raises FY2024 non-GAAP EPS guidance to high end of $6.75–$7.00 on strong cash flow and $250M ASR

CARDINAL HEALTH INC

2024-FY EPS reported $1.50 revenue$112,208,000,000

Updated FY2024 non-GAAP diluted EPS guidance to high end of $6.75–$7.00.
Executed $250M accelerated share repurchase in Q2; cash flow strength drove favorability.
Completed review of at-Home Solutions ($2.6B rev) and OptiFreight Logistics ($250M rev); will invest and develop them.
New segment structure effective Jan 1, 2024: Pharmaceutical & Specialty Solutions, GMPD, and Other.
Q2 Medical segment profit expected consistent with Q1, but on track for FY26 target of $650M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CARDINAL HEALTH INC reported fiscal year 2024 results: EPS high end of $6.75 to $7.00 range. Guidance raised.

Period: fiscal year 2024
EPS: high end of $6.75 to $7.00 range
Guidance: raised
Result: guidance update

Exact text from the filing

Updated fiscal 2024 non-GAAP diluted EPS guidance to high end of $6.75 to $7.00 range

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

CARDINAL HEALTH INC filing history →

Source: SEC EDGAR

accession 0000721371-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.